Impact of Obesity on Pediatric Acute Recurrent and Chronic Pancreatitis by Uc, Aliye et al.
Impact of Obesity on Pediatric Acute Recurrent and Chronic 
Pancreatitis
Aliye Uc, MD1, M. Bridget Zimmerman, PhD2, Michael Wilschanski, MBBS3, Steven L. 
Werlin, MD4, David Troendle, MD5, Uzma Shah, MBBS6, Sarah Jane Schwarzenberg, MD7, 
Sue Rhee, MD8, John F. Pohl, MD9, Emily R. Perito, MD8, Joseph J. Palermo, MD10, Chee Y. 
Ooi, MBBS, PhD11, Quin Liu, MD12, Tom K. Lin, MD10, Veronique D. Morinville, MD13, Brian 
A. McFerron, MD14, Sohail Z. Husain, MD15, Ryan Himes, MD16, Melvin B. Heyman, MD, 
MPH8, Tanja Gonska, MD17, Matthew J. Giefer, MD18, Cheryl E. Gariepy, MD19, Steven D. 
Freedman, MD, PhD20, Douglas S. Fishman, MD16, Melena D. Bellin, MD7, Bradley Barth, 
MD5, Maisam Abu-El-Haija, MD10, and Mark E. Lowe, MD, PhD21
1Stead Family Department of Pediatrics, University of Iowa, Stead Family Children’s Hospital, 
Iowa City, IA
2Department of Biostatistics2, University of Iowa, Iowa City, IA
3Department of Pediatrics, Hadassah Hebrew University Hospital, Jerusalem, Israel
4Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI
5Department of Pediatrics, University of Texas Southwestern Medical School, Dallas, TX
6Department of Pediatrics, Massachusetts General Hospital for Children, Harvard Medical School, 
Boston, MA
7Department of Pediatrics, University of Minnesota Masonic Children’s Hospital, Minneapolis, MN
8Department of Pediatrics, University of California San Francisco, San Francisco, CA
9Department of Pediatrics, University of Utah, Salt Lake City, UT
10Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
11Department of Pediatrics, School of Women’s and Children’s Health, Medicine, University of 
New South Wales and Sydney Children’s Hospital, Randwick Sydney, Australia
12Department of Pediatrics, Cedars-Sinai Medical Center, Los Angeles, CA
13Department of Pediatrics, Montreal Children’s Hospital, McGill University, Montreal, QC, 
Canada
Corresponding author: Aliye Uc, MD, Stead Family Department of Pediatrics, University of Iowa Health Care, 200 Hawkins Drive, 
BT 1120-C, Iowa City, IA 5224 aliye-uc@uiowa.edu). 319.356.2950. 
Conflicts: Dr. Mark Lowe is on the Board of Directors of the National Pancreas Association; receives royalties from Millipore Inc and 
UpToDate. Dr. Tanja Gonska received a research grant from Vertex Pharmaceuticals. Dr. John Pohl is on the speaker’s bureau for 
Medical Education Resources, Inc.; Dr. Melena Bellin is a consultant for AbbVie Inc and ARIEL Precision Medicine. Dr. Aliye Uc is 
a member of American Board of Pediatrics, Subboard of Pediatric Gastroenterology. The other authors declare no conflicts of interest.
All authors are responsible for reported research. They have participated in the concept and design; collection, analysis and 
interpretation of data; writing and revising of the manuscript, and decision to submit the manuscript for publication.
HHS Public Access
Author manuscript
Pancreas. Author manuscript; available in PMC 2019 September 01.
Published in final edited form as:
Pancreas. 2018 September ; 47(8): 967–973. doi:10.1097/MPA.0000000000001120.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
14Department of Pediatrics, Riley Hospital for Children, Indiana University School of Medicine, 
Indianapolis, IN
15Department of Pediatrics, Children’s Hospital of Pittsburgh, Pittsburgh, PA
16Department of Pediatrics, Baylor College of Medicine, Houston, TX
17Department of Pediatrics, Hospital for Sick Children, Toronto, ON, Canada
18Department of Pediatrics, Seattle Children’s Hospital, Seattle, WA
19Department of Pediatrics, Nationwide Children’s Hospital, Columbus, OH
20Department of Internal Medicine, Harvard Medical School, Boston, MA
21Department of Pediatrics, Washington University School of Medicine, St. Louis, MO
Abstract
Objective—To assess the impact of obesity on pediatric acute recurrent pancreatitis (ARP) or 
chronic pancreatitis (CP).
Methods—We determined body mass index (BMI) status at enrollment in INSPPIRE 
(INternational Study group of Pediatric Pancreatitis: In search for a cuRE) cohort using CDC 
criteria for pediatric-specific BMI percentiles. We used Cochran-Armitage to assess trends, 
Jonckheere-Terpstra to determine associations.
Results—Of 446 subjects (ARP = 241, CP = 205), 22 were underweight, 258 normal weight, 75 
overweight, 91 obese. The BMI groups were similar in sex, race, age at presentation. 
Hypertriglyceridemia was more common in overweight or obese. Obese children were less likely 
to have CP and more likely to have acute inflammation on imaging. Compared to children with 
normal weight, obese or overweight were older at first acute pancreatitis (AP) episode and 
diagnosed with CP at an older age. Obese or overweight were less likely to undergo medical or 
endoscopic treatment, develop exocrine pancreatic insufficiency, require total pancreatectomy with 
islet autotransplantation (TPIAT). Diabetes was similar among all groups.
Conclusions—Obesity or overweight seems to delay the initial AP episode and diagnosis of CP 
compared to normal weight or underweight. The impact of obesity on pediatric CP progression 
and severity deserves further study.
Keywords
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INTRODUCTION
Within the last decade, pediatricians have observed an increased incidence of children with 
acute pancreatitis (AP).1–5 In general, children with AP recover without long-term sequelae, 
but a subset has recurrent attacks of AP (defined as acute recurrent pancreatitis or ARP); 
some develop chronic pancreatitis (CP).6 CP is characterized by irreversible structural 
damage in the pancreas, fibrotic replacement of the parenchyma and finally failure of both 
exocrine and endocrine functions. 6 In children, genetic risk factors play a major role in 
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recurrent pancreatic inflammation and progression to chronic disease.7–10 This is in contrast 
to adult CP, where environmental factors (namely alcohol and tobacco) pose the most 
significant risk.11,12 As with adults,13 ARP most likely precedes CP in children.14 
Importantly, children with CP carry significant disease and socioeconomic burden,7,8,10,15 
underscoring the importance of identifying predisposing factors early to avoid progression of 
ARP to CP.
Obesity is an important risk factor for severe AP in adults. Obese patients with AP are prone 
to more severe inflammation with high morbidity and mortality, as well as local and 
systemic complications, compared to patients with normal weight.16–20 It is not clear 
whether obesity is also a risk factor for the development of acute recurrent pancreatitis or 
chronic pancreatitis, in adults or children. A single prospective study in adult patients, 
reported a greater presence of overweight or obesity compared to normal controls before 
disease onset of alcoholic CP. Interestingly, the only impact in this alcoholic pancreatitis 
cohort with obesity was delayed progression to CP if they had prior history of pancreatic 
surgery.21
In this report, we studied the impact of overweight or obesity on pediatric pancreatic disease 
characteristics in our well-phenotyped INSPPIRE (INternational Study group of Pediatric 
Pancreatitis: In search for a cuRE) cohort of children with ARP and CP.22
MATERIALS AND METHODS
Study Design and Participants
Demographic and clinical information were collected at the time of enrollment of children 
who fulfilled the criteria for ARP and CP from 18 pediatric academic medical centers. 
INSPPIRE study design and enrollment criteria have been previously described.22 All 
patients were <19 years of age at the time of enrollment. As previously defined, ARP 
diagnosis required 2 episodes of AP along with resolution of pain (≥ 1 month between 
episodes) or normalization of pancreatic enzymes and resolution of pain in between episodes 
irrespective of time interval.6 Diagnosis of CP required at least one of the following: (a) 
abdominal pain plus imaging findings suggestive of chronic pancreatic damage; (b) exocrine 
pancreatic insufficiency and imaging findings; (c) endocrine pancreatic insufficiency and 
imaging findings.6 Weight and height measurements were collected from physician 
questionnaires. Centers for Disease Control and Prevention (CDC) Growth Charts and 
pediatric age- and gender-specific body mass index (BMI) percentiles to classify children as 
underweight (<5th percentile), normal weight (5th–<85th percentile), overweight (85th–<95th 
percentile), or obese (≥95th percentile).23 Diabetes mellitus was defined by 2006 WHO 
criteria as fasting glucose ≥ 7.0 mmol/L (126 mg/dL) or plasma glucose ≥ 11.1mmol/L (200 
mg/dL) 2 hours after glucose load of 1.75g/kg children (to maximum 75g glucose load) or 
elevated HbA1c over 6.5% or 48 mmol/mol.24 Clinical and demographic data were entered 
into the REDCap™ (Research Electronic Data Capture, Vanderbilt University, Nashville, 
Tenn) database at 18 centers from September 2012 to March 2017, through standardized 
patient and physician questionnaires and represented baseline information of the INSPPIRE 
cohort. All centers obtained Institutional Review Board approval or the equivalent for their 
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country for this study. Most of the 446 patients included in this study have been previously 
reported.7,8,15
Statistical Analysis
Summary statistics use mean with standard deviation (SD) or median with interquartile 
range (IQR) according to the normality of distribution. Categorical variables were analyzed 
using Cochran-Armitage trend test to examine whether prevalence of findings increased/
decreased with BMI. The Jonckheere-Terpstra test was used to assess the association 
between BMI and levels of pain and missed school days. A P value <0.05 was considered 
statistically significant.
RESULTS
Patient Characteristics
A total of 446 INSPPIRE subjects were reviewed with 241 having ARP and 205 having CP. 
Of these patients, 22 (4.9%) were underweight, 258 were normal weight (57.8%), 75 
(16.8%) were overweight, and 91 were obese (20.4%) based on BMI. Demographics of the 
cohorts are shown in Table 1. The groups were not different in age at first diagnosis of AP, 
sex or race, but obese children were more likely to be of Hispanic ethnicity (P = 0.002). The 
distribution of BMI at centers with a high prevalence of Hispanic children (Children’s 
Hospital of Los Angeles, UCSF, UTSW, Baylor) were not different when compared to other 
centers (P = 0.94).
Risk Factors of ARP and CP Per BMI Groups
Table 2 shows the distribution of risk factors for ARP and CP among the groups. Patients 
with normal BMI were more likely to have cationic trypsinogen (PRSS1) mutations (P = 
0.05). There were no differences among the groups for mutations in serine protease inhibitor 
Kazal-type 1 (SPINK1), cystic fibrosis transmembrane conductance regulator (CFTR), or 
chymotrypsin C (CTRC). Hypertriglyceridemia (as defined by treating physician) was found 
almost exclusively in overweight or obese patients (P = 0.02). Other risk factors, including 
obstructive risk factors were not different among the groups.
Diagnosis of CP Per BMI Groups
Obese or overweight children were less likely to have CP (P = 0.009) and were diagnosed 
with first AP attack and with CP at an older age than normal weight or underweight children 
(P = 0.01) (Table 3). Imaging findings were determined by endoscopic retrograde 
cholangiopancreatography (ERCP), magnetic resonance imaging (MRI)/magnetic resonance 
cholangiopancreatography (MRCP); computed tomography (CT) or endoscopic ultrasound 
(EUS). Acute inflammatory changes, such as gland enlargement, peripancreatic 
inflammation/fat stranding consistent with AP/ARP were more commonly found in 
overweight or obese children (P<0.01). Chronic changes indicative of CP (pancreatic 
atrophy, pancreatic fibrosis, pancreatic duct irregularity, pancreatic duct dilatation, 
pancreatic duct stone, calcifications, abnormal side branches) were found at similar rates in 
all groups (Table 4). The exception was pancreatic ductal strictures which were significantly 
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less common in obese or overweight (P = 0.008) (Table 4). Overweight or obese children 
were also less likely to have ERCP done for diagnostic or therapeutic purposes (P = 0.03).
Impact of Weight Category on Disease Burden and Complications of CP
Weight category had no impact on the frequency or pattern of abdominal pain, missed school 
days, emergency room visits or hospitalizations related to pancreatitis (Table 5). Obese 
children were significantly less likely to undergo medical treatments (specifically pancreatic 
enzyme therapy), endoscopic interventions and total pancreatectomy/islet 
autotransplantation (TPIAT) than other groups (P < 0.001, 0.01, and 0.002 respectively) 
(Table 6). Finally, overweight or obese children were less likely to have exocrine pancreatic 
insufficiency (P = 0.013) and there were no differences in the diagnosis of diabetes among 
the groups (Table 7).
Findings Controlling for Hispanic Ethnicity
Because Hispanic ethnicity is associated with obesity, we performed additional analysis of 
the parameters associated with obesity to control for Hispanic ethnicity. These showed that 
the same trends persisted in the study sub-population of non-Hispanics as in the entire 
cohort (see Supplemental Table 1).
DISCUSSION
In this large, multicenter and multinational cohort of children with acute recurrent 
pancreatitis, we found that overweight or obese children were less likely to suffer from 
chronic pancreatitis, exocrine pancreatic insufficiency and less likely to undergo medical 
therapies, endoscopic procedures or TPIAT.
Obesity is a well-recognized risk factor of severe AP in adults, associated with high 
morbidity and mortality.16–20 During AP episodes, obese patients may be prone to both local 
complications (i.e. pancreatic pseudocyst, necrosis or abscess), systemic complications 
(sepsis, lung and kidney failure) and increased risk of death. Increased risk of local 
complications may be related to greater volume of retroperitoneal, peripancreatic or 
intrapancreatic fat found in obese people with AP,20,25,26 as fat will have a higher propensity 
for necrosis. Indeed, there is a direct correlation between BMI, amount of intrapancreatic fat 
and severity of AP.20 The mechanisms leading to higher levels of complications of AP in 
obesity are not well-understood. A recent study has suggested that unsaturated fatty acids 
released from intrapancreatic fat could be responsible of local necrosis and systemic 
complications.20 Similar to adults, obese children with AP have worse outcomes compared 
to non-obese: severe AP, length of stay, medical costs, mortality are significantly higher in 
obese individuals.27
The role of obesity as a risk factor for ARP or CP is largely unknown. In a study by 
Ammann et al, progression to CP in a group of adult patients was slower over time if BMI 
was >25 and they underwent a drainage surgery previously.21 However, it should be noted 
that this was a cohort of alcoholic CP patients, about half of patients were obese and the 
effect was not seen in obese patients without prior surgical history. The outcome may be 
Uc et al. Page 5
Pancreas. Author manuscript; available in PMC 2019 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
quite different in the pediatric cohort where alcohol is a negligible risk factor of ARP and 
CP.7,8
In our cohort, obese or overweight children were diagnosed with CP at an older age and 
their imaging findings were overwhelmingly supportive of acute inflammatory changes in 
the pancreas. These data suggest that obesity may induce a delayed-onset disease, a 
prolonged proinflammatory state, with delayed progression to a chronic inflammatory state. 
According to the popular sentinel acute pancreatitis event (SAPE) hypothesis or repeated 
inflammation-recovery-fibrosis theory, massive inflammatory response develops with AP 
consistent of both early and late phases.28 Initially inflammation in the pancreas attracts 
inflammatory cells (neutrophils, lymphocytes) along with cytokines and causes oxidative 
stress.28 During later phases of the inflammation, profibrotic cells and stellate cells 
predominate. Once the inciting factor is removed, the pancreas heals to baseline, but 
recurrent inflammation sets the stage for progressive fibrosis. It is possible that the peri- or 
intrapancreatic fat creates a proinflammatory or prooxidant state that prevents or delays the 
transition to chronicity. We have not analyzed the pancreatic imaging studies to verify the 
presence of pancreatic fat in our patients. This will be an important addition to the study 
questionnaires as the INSPPIRE consortium moves forward.
Although diagnosis of CP was less common in obese or overweight children, the only 
significant difference between the groups was the presence of ductal strictures in children 
with normal weight. It is possible that differences could be detected in a larger cohort.
The high percentage of obese children in our population reflects the increased prevalence of 
obesity in the US and other countries observed within the last few decades.29,30 Twenty-
three percent of our study population was obese, which is a slightly higher than expected US 
prevalence for this age group.29 We observed a much higher percentage of Hispanic children 
with obesity in our cohort (40%) compared to the general US population (<24% for all 
Hispanic pediatric age groups).29 This raises an interesting question about the potential role 
of genetic variations among ethnic groups in disease presentation or evolution. The 
distribution of BMI was similar at all centers including centers that enrolled a higher number 
of Hispanic children, therefore it is unlikely that the results were skewed by an enrollment 
bias.
Obese children were less likely to have exocrine pancreatic insufficiency diagnosis. They 
were less likely to receive medical treatments (specifically pancreatic enzyme therapy), 
endoscopic or surgical procedures, such as TPIAT. TPIAT is directed primarily to the 
treatment of CP by removing the pancreas that has lost its exocrine function while 
attempting to preserve its islet cell mass and maintain the endocrine function. 31
Hypertriglyceridemia is known to be associated with acute pancreatitis,32,33 and a recent 
study in adults has shown that even mild elevations in serum triglycerides may be a risk 
factor.34 Elevated serum triglycerides are well-described in obese children as a risk factor for 
cardiovascular disease.35,36 It is possible that elevated triglyceride levels in our cohort of 
overweight or obese children is due to obesity and unrelated to pancreatitis.
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We did not observe different rates of diabetes among the groups, but diabetes is a late 
complication of CP (18%, 20 years after diagnosis).37 It may be too early to observe 
diabetes in our cohort. Overall, the percentage of children with diabetes in our cohort (7.0%; 
95% confidence interval, 5%–10%) was higher than that observed in the US population 
(0.25–0.5% under the age 20 years old).38–40 Our report of diabetes is based on physician’s 
diagnosis and does not differentiate between the types of diabetes, including Type 1, 2, or 
Type 3c (pancreatogenic) diabetes, therefore it is possible that it was under-reported. Type 
3c diabetes is emerging as a distinct form of diabetes, although there are yet no clear 
guidelines to differentiate it from other forms of diabetes.41,42 Our future efforts will include 
a detailed phenotyping of patients for all types of diabetes, including prediabetes.
Obesity or overweight present with the initial AP attack later and are diagnosed with CP 
later compared to normal weight or underweight. In the INSPPIRE cohort, overweight or 
obese children were less likely than normal weight or underweight children to suffer from 
chronic pancreatitis, exocrine pancreatic insufficiency and undergo medical therapies, 
endoscopic procedures or TPIAT. The full impact of obesity on pediatric pancreatitis 
severity, recurrence, progression and chronicity will only become clear with longer follow-
up of our cohort.
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